Prodrug design is a widely known molecular modification strategy that aims to optimize the physicochemical and pharmacological properties of drugs to improve their solubility and pharmacokinetic features and decrease their toxicity. A lack of solubility is one of the main obstacles to drug development. This review aims to describe recent advances in the improvement of solubility via the prodrug approach. The main chemical carriers and examples of successful strategies will be discussed, highlighting the advances of this field in the last ten years.
Resveratrol (RVT) is one of the main natural compounds studied worldwide due to its potential therapeutic use in the treatment of many diseases, including cancer, diabetes, cardiovascular diseases, neurodegenerative diseases and metabolic disorders. Nevertheless, the mechanism of action of RVT in all of these conditions is not completely understood, as it can modify not only biochemical pathways but also epigenetic mechanisms. In this paper, we analyze the biological activities exhibited by RVT with a focus on the epigenetic mechanisms, especially those related to DNA methyltransferase (DNMT), histone deacetylase (HDAC) and lysine-specific demethylase-1 (LSD1).
Resveratrol and curcumin are natural products with important therapeutic properties useful to treat several human diseases, including cancer. In the last years, the number of studies describing the effect of both polyphenols against cancer has increased; however, the mechanism of action in all of those cases is not completely comprehended. The unspecific effect and the ability to interfere in assays by both polyphenols make this challenge even more difficult. Herein, we analyzed the anticancer activity of resveratrol and curcumin reported in the literature in the last 11 years, in order to unravel the molecular mechanism of action of both compounds. Molecular targets and cellular pathways will be described. Furthermore, we also discussed the ability of these natural products act as chemopreventive and its use in association with other anticancer drugs.
Over
the past 2000 years, tuberculosis (TB) has claimed more lives
than any other infectious disease. In 2020 alone, TB was responsible
for 1.5 million deaths worldwide, comparable to the 1.8 million deaths
caused by COVID-19. The World Health Organization has stated that
new TB drugs must be developed to end this pandemic. After decades
of neglect in this field, a renaissance era of TB drug discovery has
arrived, in which many novel candidates have entered clinical trials.
However, while hundreds of molecules are reported annually as promising
anti-TB agents, very few successfully progress to clinical development.
In this Perspective, we critically review those anti-TB compounds
published in the last 6 years that demonstrate good in vivo efficacy against Mycobacterium tuberculosis. Additionally,
we highlight the main challenges and strategies for developing new
TB drugs and the current global pipeline of drug candidates in clinical
studies to foment fresh research perspectives.
Tuberculosis (TB) remains a serious health problem responsible to cause millions of deaths annually. The scenario becomes alarming when it is evaluated that the number of new drugs does not increase proportionally to the emergence of resistance to the current therapy. Furoxan derivatives, known as nitric oxide (NO) donors, have been described to exhibit antitubercular activity. Herein, a novel series of hybrid furoxan derivatives (1,2,5-oxadiazole 2-N-oxide) (compounds 4a-c, 8a-c and 14a-c) were designed, synthesized and evaluated in vitro against Mycobacterium tuberculosis (MTB) H 37 Rv (ATCC 27294) and a clinical isolate MDR-TB strain. The furoxan derivatives have exhibited MIC 90 values ranging from 1.03 to 62 mM (H 37 Rv) and 7.0e50.0 mM (MDR-TB). For the most active compounds (8c, 14a, 14b and 14c) the selectivity index ranged from 3.78 to 52.74 (MRC-5 cells) and 1.25e34.78 (J774A.1 cells). In addition, it was characterized for those compounds logP o/w values between 2.1 and 2.9. All compounds were able to release NO at levels ranging from 0.16 to 44.23%. Among the series, the phenylsulfonyl furoxan derivatives (compounds 14a-c) were the best NO-donor with the lowest MIC 90 values. The most active compound (14c) was also stable at different pHs (5.0 and 7.4). In conclusion, furoxan derivatives were identified as new promising compounds useful to treat tuberculosis.
Tuberculosis,
caused by Mycobacterium tuberculosis (Mtb), is the infectious disease responsible for
the highest number of deaths worldwide. Herein, 22 new N-oxide-containing
compounds were synthesized followed by in vitro and in vivo evaluation of their antitubercular potential against Mtb. Compound 8 was found to be the most promising
compound, with MIC90 values of 1.10 and 6.62 μM against
active and nonreplicating Mtb, respectively. Additionally,
we carried out in vivo experiments to confirm the
safety and efficacy of compound 8; the compound was found
to be orally bioavailable and highly effective, leading to a reduction
of Mtb to undetectable levels in a mouse model of
infection. Microarray-based initial studies on the mechanism of action
suggest that compound 8 blocks translation.
Altogether, these results indicate that benzofuroxan derivative 8 is a promising lead compound for the development of a novel
chemical class of antitubercular drugs.
Tuberculosis (TB) is currently the leading cause of death related to infectious diseases worldwide, as reported by the World Health Organization. Moreover, the increasing number of multidrug-resistant tuberculosis (MDR-TB) cases has alarmed health agencies, warranting extensive efforts to discover novel drugs that are effective and also safe. In this study, 23 new compounds were synthesized and evaluated in vitro against the drug-resistant strains of M. tuberculosis. The compound 6-((3-fluoro-4-thiomorpholinophenyl)carbamoyl)benzo[c][1,2,5] oxadiazole 1-N-oxide (5 b) was particularly remarkable in this regard as it demonstrated MIC 90 values below 0.28 μM against all the MDR strains evaluated, thus suggesting that this compound might have a different mechanism of action. Benzofuroxans are an attractive new class of anti-TB agents, exemplified by compound 5 b, with excellent potency against the replicating and drug-resistant strains of M. tuberculosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.